The fourth call led to the selection, by independent international experts, of nine innovative research projects of European scope for a total amount of 4,4 million euros. These projects include 8 Translational Researchs and 1 Clinical Trial.
The third call led to the selection, by independent international experts, of 10 innovative research projects of European scope for a total amount of 7,25 million euros. This call includes 3 additional projects selected early 2023 for a total of 7 Translational Researchs and 3 Clinical Trials.
In 2021, the second call led to the selection of five innovative projects for a total amount of 3,45 million euros. These 5 projects are about the following diseases: B-cell non-Hodgkin’s lymphoma, Ewing’s sarcoma, medulloblastoma and neuroblastoma (2 projects). They include 3 x Translational Researchs and 2 x Clinical Trials.
In 2020, the first call led to the selection of six innovative projects for a total amount of 3,08 million euros. These 6 projects are about the following diseases: high-grade gliomas (2 projects), acute myeloid leukaemia, rhabdoid tumours, osteosarcoma and neuroblastomas. They include 5 Translational Researchs and 1 Clinical Trial.
Programme support and management is provided by the European Science Foundation, which is the intermediary with the funding organisations.
For further information about this announcement of opportunity please contact Fight Kids Cancer at ESF: fightkidscancer@esf.org